Health Condition 1: L700- Acne vulgaris
Conditions
Interventions
Intervention1: Spironolactone for adult female acne: oral spironolactone tablets 100 mg OD given to patients with adult female acne for 3 months.
Intervention2: Oral combined contraceptive pills are g
Sponsors
Dr Chandan Srinivasa K
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient of female gender age more than 25 years 2. Patients willing to give informed consent 3. Patients willing for follow up. 4. All clinically diagnosed cases of moderate to severe adult female acne.
Exclusion criteria
Exclusion criteria: 1. Patients not willing to give informed consent. 2. Patients less than 25 years of age. 3. Patients with contraindications to Oral contraceptive pills . 4. Patients with contraindications to oral spironolactone 5. Patients on injectible hormones 6 months before enrolment 6. Patients on implantable and oral hormones in the last 3 months before enrolment to study 7. Patients on isotretinoin 3 months before enrolment 8. Patients on systemic antibiotics 3 month before enrolment 9. Patients on topical acne treatments 1 month before enrolment 10. Patients planning to conceive in the next 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease in Clinician global assessment score (CGA) over 6 months to calculate efficacyTimepoint: Clinician global assessment score (CGA) is recorded and serial photographs are taken in every monthly visit over 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| SafetyTimepoint: Safety is assessed by looking into the side effects seen to oral spironolactone or oral combined ethinylestradiol and levonorgesterol over 6 months | — |
Countries
India
Contacts
Public ContactDr Shilpa K
Bangalore medical college and research institute
Outcome results
None listed